Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) EBITDA (2016)

Historic EBITDA for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to $33.6 million.

  • Tenax Therapeutics' EBITDA rose 37751.71% to $33.6 million in Q4 2016 from the same period last year, while for Dec 2016 it was $30.4 million, marking a year-over-year increase of 13699.13%. This contributed to the annual value of -$19.5 million for FY2024, which is 35281.84% down from last year.
  • Per Tenax Therapeutics' latest filing, its EBITDA stood at $33.6 million for Q4 2016, which was up 37751.71% from $4.3 million recorded in Q3 2016.
  • In the past 5 years, Tenax Therapeutics' EBITDA ranged from a high of $68.9 million in Q2 2012 and a low of -$74.1 million during Q2 2013
  • For the 4-year period, Tenax Therapeutics' EBITDA averaged around $2.3 million, with its median value being -$682843.0 (2012).
  • In the last 5 years, Tenax Therapeutics' EBITDA soared by 242467.64% in 2012 and then crashed by 20753.42% in 2013.
  • Tenax Therapeutics' EBITDA (Quarter) stood at -$682843.0 in 2012, then crashed by 10746.09% to -$74.1 million in 2013, then surged by 83.66% to -$12.1 million in 2015, then soared by 377.52% to $33.6 million in 2016.
  • Its EBITDA stands at $33.6 million for Q4 2016, versus $4.3 million for Q3 2016 and $4.6 million for Q2 2016.